Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Adial Pharmaceuticals Inc (ADIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,287
  • Shares Outstanding, K 10,144
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,630 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.53 +6.32%
on 04/18/19
3.60 -25.28%
on 03/29/19
-0.32 (-10.63%)
since 03/18/19
3-Month
2.53 +6.32%
on 04/18/19
7.14 -62.32%
on 01/22/19
-4.01 (-59.85%)
since 01/18/19

Most Recent Stories

More News
Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy

Adial to Advance Corporate Partnerships; Licensing and M&A Opportunities

ADIL : 2.69 (-4.95%)
AVCO : 4.78 (+0.63%)
Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award

Lecture to focus on pharmacogenic treatment personalization for alcohol use disorder

ADIL : 2.69 (-4.95%)
Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D.

CHARLOTTESVILLE, VA / ACCESSWIRE / April 3, 2019 / (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole...

ADIL : 2.69 (-4.95%)
Adial Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer

CHARLOTTESVILLE, VA / ACCESSWIRE / March 26, 2019 / (NASDAQ: ADIL; NASDAQ: ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that...

ADIL : 2.69 (-4.95%)
Adial Pharmaceuticals Announces Filing to Update the Prior Registration Statement Registering the Shares Underlying the ADILW Warrants

CHARLOTTESVILLE, VA / ACCESSWIRE / March 25, 2019 / (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced today that it filed...

ADIL : 2.69 (-4.95%)
Adial Pharmaceuticals Featured on CBS in San Francisco

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced that William Stilley, President and Chief...

ADIL : 2.69 (-4.95%)
Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced the pricing of an underwritten public...

ADIL : 2.69 (-4.95%)
Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial's AD04 for its Phase 3 Trial

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced a partnership with...

ADIL : 2.69 (-4.95%)
Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse

Continuation patent would allow for broader protection beyond claims protected under current patents

ADIL : 2.69 (-4.95%)
Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder

Distinguished Professor Markus Heilig joins an accomplished assemblage of addiction specialists including Dr. Giovanni Addolorato and Professors Hannu Alho, Tomas Zima and Sebastian Mueller

ADIL : 2.69 (-4.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ADIL with:

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

2nd Resistance Point 3.08
1st Resistance Point 2.88
Last Price 2.69
1st Support Level 2.51
2nd Support Level 2.34

See More

52-Week High 9.44
Fibonacci 61.8% 6.26
Fibonacci 50% 5.27
Fibonacci 38.2% 4.29
Last Price 2.69
52-Week Low 1.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar